cabozantinib cabozantinib

Drug Class

Multitargeted tyrosine kinase inhibitor

Mechanism

Cabozantinib inhibits multiple receptor tyrosine kinases, including MET, VEGFR-1, -2, and -3, AXL, and RET, blocking angiogenesis, invasiveness, and metastasis.

Approved Indication

Treatment of patients with advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) previously treated with sorafenib, and progressive, metastatic medullary thyroid cancer (MTC).

What This Means For Patients

cabozantinib is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2012) — Sources
• EMA — Approved (2016) — Sources

Pivotal Clinical Evidence

• METEOR — Choueiri et al., N Engl J Med 2015 (NCT01865747) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206001s009lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/cabometyx
• https://doi.org/10.1056/NEJMoa1510016